Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This multicentre, randomised, double-blind, placebo-controlled trial was performed to determine whether the use of oral probiotic preparation (prOVag®) containing three Lactobacillus strains together with standard metronidazole treatment and also targeted antibiotic treatment (following the failure of metronidazole therapy) could reduce the recurrence rates of bacterial vaginosis (BV) and aerobic vaginitis (AV). METHODS: Patients at private gynaecological clinics in Poland with histories of recurrent BV/AV and current symptoms were randomly allocated to receive metronidazole and probiotic or placebo, and assessed monthly on visits II and III-V. The total number of study visits was 5-6 (I, II, II bis - if applicable, III, IV, V). One probiotic or placebo capsule was administered with metronidazole/targeted antibiotic twice daily for 10 days; during follow up, patients took one capsule daily for 10 days perimenstrually. Clinical examination and vaginal swabbing were performed at each visit. Primary outcomes were clinical or microbiological BV/AV recurrence and probiotic safety. Secondary outcomes were vaginal pH, Nugent score, and Lactobacillus counts in the vaginal microbiota. Safety analysis was performed in 578 (probiotic, n = 285; placebo, n = 293) 18-50-year-old women who were randomised. RESULTS: BV/AV was confirmed microbiologically in 241 (probiotic, n = 118; placebo, n = 123) participants, who continued the trial. Data from 154 (probiotic, n = 73; placebo, n = 81) participants who completed the study were analysed to determine the efficacy of prOVag. Additional analyses included 37 (probiotic, n = 22; placebo, n = 15) participants who received targeted antibiotics and probiotics or placebo. prOVag lengthened the time to clinical relapse of BV/AV symptoms up to 51 % (p < 0.05) compared with placebo; AV relapse was delayed by up to 76 % (p < 0.05). Probiotic use also reduced and maintained low vaginal pH and Nugent score, and increased vaginal Lactobacillus counts following standard treatment. CONCLUSION: This study demonstrated that oral probiotics lengthened remission in patients with recurrent BV/AV and improved clinical and microbiological parameters. TRIAL REGISTRATION: NCT01993524 ; 20 November 2013.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824
Oral probiotics can resolve urogenital infections
Reid, G., Bruce, A. W., Fraser, N., Heinemann, C., Owen, J., & Henning, B. (2001) · FEMS Immunology & Medical Microbiology · doi:10.1016/s0928-8244(00)00233-9 · Cited by 464
Leitich, H., & Kiss, H. (2007) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.12.005 · Cited by 342
Vujic, G., Jajac Knez, A., Despot Stefanovic, V., & Kuzmic Vrbanovic, V. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2012.12.031 · Cited by 159 · cited 1×
“Results of a recent double-blind, randomised, placebocontrolled clinical trial [14] on treatment of BV by oral application of two probiotic bacteria described earlier by Reid [15] show restoration of vaginal microbiota balance within 44 days in 61.”
Background
Cited by
Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health
Monteagudo-Mera, A., Rastall, R. A., Gibson, G. R., Charalampopoulos, D., & Chatzifragkou, A. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09978-7 · Cited by 743
“Numerous evidences have shown that probiotics could be useful for the treatment and prevention of urogenital infections especially in women (Ya et al. 2010; Bisanz et al. 2014; Heczko et al. 2015; Pendharkar et al. 2015).”
BackgroundVaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health
Chee, W. J. Y., Chew, S. Y., & Than, L. T. L. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01464-4 · Cited by 657
The role of lactic acid production by probiotic Lactobacillus species in vaginal health
Tachedjian, G., Aldunate, M., Bradshaw, C. S., & Cone, R. A. (2017) · Research in Microbiology · doi:10.1016/j.resmic.2017.04.001 · Cited by 557
The Complex Link between the Female Genital Microbiota, Genital Infections, and Inflammation
Dabee, S., Passmore, J.-A. S., Heffron, R., & Jaspan, H. B. (2021) · Infection and Immunity · doi:10.1128/iai.00487-20 · Cited by 89
Joseph, R. J., Ser, H.-L., Kuai, Y.-H., Tan, L. T.-H., Arasoo, V. J. T., Letchumanan, V., Wang, L., Pusparajah, P., Goh, B.-H., Ab Mutalib, N.-S., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10060719 · Cited by 68
Metadata
- Authors
- Heczko, P. B., Tomusiak, A., Adamski, P., Jakimiuk, A. J., Stefański, G., Mikołajczyk-Cichońska, A., Suda-Szczurek, M., & Strus, M.
- Venue
- BMC Women's Health
- Published
- 2015-12
- Volume
- 15
- Issue
- 1
- Pages
- 115-115
- ISSN
- 1472-6874 (ISSN-L)
- OpenAlex
- W2186206843
- Cited by
- 107
- References
- 4
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1186/s12905-015-0246-6
- The paper
- Heczko, P. B., Tomusiak, A., Adamski, P., Jakimiuk, A. J., Stefański, G., Mikołajczyk-Cichońska, A., Suda-Szczurek, M., & Strus, M. (2015). Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial. BMC Women's Health. https://doi.org/10.1186/s12905-015-0246-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.